|
Research update: MorphoSys AG November 26, 2007  Comparatively sound business model MorphoSys is one of only few profitable German biotechnology companies. The group's proprietary HuCAL technology generates near-term revenues and provides the potential for long-term royalties. Commercialisation of the library is achieved by cooperation with pharmaceutical and biotechnology companies. MorphoSys currently has... ...Subscribe to VISCARDI Research... |
|
Research update: MorphoSys AG October 27, 2005 Sound third quarter results, but 2006 delays Group sales in the first nine months of 2005 rose by 52% to €23.8m, mainly due to by new collaboration agreements, milestone payments and consolidation of Biogenesis, acquired in January 2005. MorphoSys now has 28 partner projects against 24 at the start of 2005 ... ...Subscribe to VISCARDI Research... |
|
Research note: MorphoSys September 01, 2005 2005 Low risk biotech, but more valuation uncertainty Four companies in the world dominate the generation of antibody therapeutics using fully human antibodies. Two of these generate human antibodies in mice and the other two ... ...Subscribe to VISCARDI Research... |